2024-07-08 16:40
“The Connection Study” is completed
The last patient in IBT’s global phase 3 clinical program “The Connection Study” has finished treatment. IBP-9414 is being developed...
2024-05-08 18:11
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved: ContactsStaffan...
Message from the CEO IBT has successfully completed the recruitment of infants for our Phase III study (The Connection Study), which is the final clinical...
2024-04-04 19:32
Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study
The last patient of 2158 premature babies has been enrolled in the global phase 3 clinical program (“The Connection Study”) for the development...
2024-04-03 11:00
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The report is available on IBT´s website, https://ibtherapeutics.com under the section Ïnvestors & Media – Financial Reports&rdquo...
2024-02-08 08:30
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
Message from the CEO 2023 was a very eventful year for IBT, as we pushed forward with the development of our clinical program IBP-9414 and achieved several...
2023-11-10 08:30
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023
Message from the CEOThe third quarter has been very eventful for IBT. In July IBT received a capital injection of 101 MSEK from our shareholders. The funds...
2023-10-24 10:50
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024
The 2023 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited...